GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
GlaxoSmithKline has filed its Shingrix shingles vaccine in the US ... also known as herpes zoster, than Merck & Co's rival, Zostavax. It is a non-live, recombinant vaccine to help prevent ...
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
Some results have been hidden because they may be inaccessible to you